A study assessed whether the addition of anti-VEGF agent to first-line treatment impacted outcomes in metastatic CRC. Maintenance with cetuximab monotherapy appeared to improve PFS and OS in patients with metastatic colorectal cancer. A study assessed the efficacy of a treatment combination in the second-line treatment of metastatic colorectal cancer. The combination of pembrolizumab and lenvatinib did not improve survival in metastatic CRC. A systematic review reported that immune checkpoint inhibitor therapy shows promising results in metastatic CRC. The FRESCO-2 study showed that fruquintinib resulted in an overall survival benefit in metastatic colorectal cancer. Dr. Eng discusses the phase 3 FRESCO-2 study and how fruquintinib fits in with current treatments for advanced CRC. Nimotuzumab plus gemcitabine demonstrated a favorable safety profile in patients with metastatic pancreatic cancer. The rate of colorectal cancer (CRC) screenings decreased by more than 20% during the COVID-19 pandemic. A study found key tumor heterogeneities, including Ki-67 indices, might contribute to disease progression in GEP-NETs. Pranob Bhattacharya discusses zolbetuximab, a first-in-class investigational therapy for the treatment of gastric cancer. The Oncology Brothers speak with Cathy Eng, MD, about treatment of metastatic colorectal cancer with fruquintinib. Results from a recent study suggest a novel therapy that may effectively treat pancreatic ductal adenocarcinoma. Daily vitamin D3 supplementation was associated with reduced risk of relapse or death in digestive tract cancer. An analysis found that esophageal cancer rates have declined in the United States since 2004. Lu-177-dotatate in PRRT appeared to treat GEP-NETs, though prior internal radiation may impede responses or worsen survival. Researchers identified a circRNA signature as a potential biomarker for GEP-NETs. A study evaluated the predictive ability of the combined SMI and PNI to assess survival in advanced gastric cancer patients. Treatment with avelumab improved progression-free survival in patients with mCRC. Patients diagnosed with colorectal liver metastases in expert hospitals receive better treatment.